Tinsley-Vance Sara M, Mason Tina M, Komrokji Rami S
Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612 USA.
College of Nursing, University of South Florida, Tampa, FL 33612 USA.
Health Sci Rev (Oxf). 2024 Dec;13. doi: 10.1016/j.hsr.2024.100205. Epub 2024 Nov 14.
INTRODUCTION/BACKGROUND: An improved understanding of cancer-related cachexia and sarcopenia among patients with hematologic malignancies can improve their health outcomes. Patients with hematologic malignancies are affected by cancer-related cachexia and sarcopenia, but this aspect of their care is rarely studied. This review aims to increase awareness and knowledge of cancer-related cachexia and sarcopenia for patients with hematologic malignancies through a comprehensive synthesis of current research.
An integrative literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Ovid MEDLINE, CINAHL Complete, Embase, and Web of Science databases were searched for studies published between 2012 and 2022 using search terms of hematologic malignancies and cancer-related cachexia or sarcopenia.
Twenty-nine studies were examined with data on 5,687 patients, primarily diffuse large B-cell lymphoma.
The results are grouped by themes identified in the studies of cancer-related cachexia and sarcopenia in hematologic cancers. The major themes identified were health outcomes, patient identification, transplant effects, and sex differences. Cancer-related cachexia and sarcopenia are associated with decreased overall survival and progression-free survival, similar to solid tumors. Cancer-related cachexia and sarcopenia reduce tolerance to chemotherapy and increase hematologic toxicities. With this effect, biomarkers and cachexia prognostic scores are available to improve patient identification, prognostication, and support. These affected individuals will benefit from increased awareness by the healthcare team to tailor care and mitigate the deleterious effects of the condition.
引言/背景：更好地了解血液系统恶性肿瘤患者的癌症相关性恶病质和肌肉减少症，有助于改善他们的健康结局。血液系统恶性肿瘤患者会受到癌症相关性恶病质和肌肉减少症的影响，但这方面的护理很少被研究。本综述旨在通过全面综合当前研究，提高血液系统恶性肿瘤患者对癌症相关性恶病质和肌肉减少症的认识和了解。
根据系统评价和Meta分析的首选报告项目进行综合文献综述。使用血液系统恶性肿瘤以及癌症相关性恶病质或肌肉减少症的检索词，在Ovid MEDLINE、CINAHL Complete、Embase和Web of Science数据库中检索2012年至2022年发表的研究。
审查了29项研究，涉及5687例患者的数据，主要是弥漫性大B细胞淋巴瘤。
结果按照血液系统癌症中癌症相关性恶病质和肌肉减少症研究中确定的主题进行分组。确定的主要主题包括健康结局、患者识别、移植影响和性别差异。与实体瘤类似，癌症相关性恶病质和肌肉减少症与总生存期和无进展生存期降低相关。癌症相关性恶病质和肌肉减少症会降低对化疗的耐受性并增加血液学毒性。基于这种影响，可利用生物标志物和恶病质预后评分来改善患者识别、预后评估和支持。这些受影响的个体将受益于医疗团队提高认识，以调整护理并减轻该病症的有害影响。
